N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Cited by (909)

Items 401–500 of 909

1. Zoonosis and zooanthroponosis of emerging respiratory viruses
   Ahmed Magdy Khalil, Luis Martínez‐Sobrido, Ahmed Mostafa · 2024 · Frontiers in Cellular and Infection Microbiology
2. Enhanced potency of an IgM-like nanobody targeting conserved epitope in SARS-CoV-2 spike N-terminal domain
   Bo Liu, Honghui Liu, Pu Han, Xiaoyun Wang, Chunmei Wang, Xinxin Yan, Wenwen Lei, Ke Xu, Jianjie Zhou, Jianxun Qi et al. · 2024 · Signal Transduction and Targeted Therapy
3. Virion morphology and on-virus spike protein structures of diverse SARS-CoV-2 variants
   Zunlong Ke, Thomas P. Peacock, Jonathan C. Brown, Carol Sheppard, Tristan Ian Croll, Abhay Kotecha, Daniel H. Goldhill, William Barclay, John A. G. Briggs · 2024 · The EMBO Journal
4. The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants
   Efi Makdasi, Anat Zvi, Ron Alcalay, Tal Noy-Porat, Eldar Peretz, Adva Mechaly, Yinon Levy, Eyal Epstein, Theodor Chitlaru, Ariel Tennenhouse et al. · 2021 · Cell Reports
5. XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants
   B. Vanhove, S. Marot, Ray T. Y. So, B. Gaborit, G. Evanno, I. Malet, Guillaume Lafrogne, Edwige Mevel, C. Ciron, Pierre-Joseph Royer et al. · 2021 · Frontiers in Immunology
6. Structural Dynamics and Molecular Evolution of the SARS-CoV-2 Spike Protein
   Kyle Wolf, Jason C. Kwan, Jeremy P. Kamil · 2022 · mBio
7. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge
   Juan Shi, Jian Hua Zheng, Xiujuan Zhang, Wanbo Tai, Abby E. Odle, Stanley M. Perlman, Lanying Du · 2022 · Translational research
8. Development of receptor binding domain-based double-antigen sandwich lateral flow immunoassay for the detection and evaluation of SARS-CoV-2 neutralizing antibody in clinical sera samples compared with the conventional virus neutralization test
   Ying Zhang, Yixiao Chen, Yong He, Yizhe Li, Xiaoli Zhang, Jiajie Liang, Jinyong He, Shaofang Lü, Zhixing Gao, Jianhua Xu et al. · 2022 · Talanta
9. Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins
   Zi-Jun Wang, Frauke Muecksch, Alice Cho, C. Gaebler, H. Hoffmann, Victor A. Ramos, Shuaizhou Zong, M. Cipolla, Bryant Johnson, Fabian Schmidt et al. · 2022 · bioRxiv
10. Discovery and Characterization of Spike N‐Terminal Domain‐Binding Aptamers for Rapid SARS‐CoV‐2 Detection
    Nataly A. Kacherovsky, Lucy F. Yang, Ha V. Dang, Emmeline L. Cheng, Ian I. Cardle, Alexandra C. Walls, Matthew McCallum, Drew L. Sellers, Frank DiMaio, Stephen J. Salipante et al. · 2021 · Angewandte Chemie
11. Tracking the turnover of SARS-CoV-2 VOCs Gamma to Delta in a Brazilian state (Minas Gerais) with a high-vaccination status
    Paula Luize Camargos Fonseca, Filipe Romero Rebello Moreira, Rafael Marques de Souza, Natália R Guimarães, Nara de Oliveira Carvalho, Talita Adelino, Hugo José Alves, Luige Biciati Alvim, Darlan da Silva Cândido, Helena Perez Coelho et al. · 2022 · Virus Evolution
12. Structural analysis of receptor engagement and antigenic drift within the BA.2 spike protein
    James W. Saville, Dhiraj Mannar, Xing Quan Zhu, Alison Berezuk, Spencer CHOLAK, Katherine R. Tuttle, Faezeh Vahdati Hassani, Sriram Subramaniam · 2023 · Cell Reports
13. Adaptive variations in SARS-CoV-2 spike proteins: effects on distinct virus-cell entry stages
    Enya Qing, Tom Gallagher · 2023 · mBio
14. Machine learning-based approach KEVOLVE efficiently identifies SARS-CoV-2 variant-specific genomic signatures
    Dylan Lebatteux, Hugo Soudeyns, Isabelle Boucoiran, Soren M. Gantt, Abdoulaye Baniré Diallo · 2024 · PLoS ONE
15. Deep repertoire mining uncovers ultra-broad coronavirus neutralizing antibodies targeting multiple spike epitopes
    Jonathan Hurtado, Thomas F. Rogers, David B. Jaffe, Bruce A. Adams, Sandhya Bangaru, Elijah Garcia, Tazio Capozzola, Terrence Messmer, Pragati Sharma, Ge Song et al. · 2024 · Cell Reports
16. Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV
    Cara W. Chao, Kaitlin R. Sprouse, Marcos C. Miranda, Nicholas Catanzaro, Miranda L. Hubbard, Amin Addetia, Cameron Stewart, Jack T Brown, Annie M. Dosey, Adian Valdez et al. · 2024 · Cell Reports
17. Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variants
    Rui Ming Yin, Johnathan D. Guest, Ghazaleh Taherzadeh, Ragul Gowthaman, Ipsa Mittra, Jane Quackenbush, Brian G. Pierce · 2021 · PLoS Computational Biology
18. Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies
    Brandon J. Beddingfield, Nicholas J. Maness, Alyssa C. Fears, Jay Rappaport, Pyone P. Aye, Kasi Russell‐Lodrigue, Lara A. Doyle‐Meyers, Robert V. Blair, Ann M. Carias, Patrick J. Madden et al. · 2021 · Frontiers in Cellular and Infection Microbiology
19. Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation
    K. van der Straten, M. V. van Gils, S. D. de Taeye, G. D. de Bree · 2022 · Frontiers in Medical Technology
20. SARS-CoV-2: An Overview of the Genetic Profile and Vaccine Effectiveness of the Five Variants of Concern
    Raluca Dumache, Alexandra Enache, Ioana Gabriela Macasoi, Cristina Adriana Dehelean, Victor Cristian Dumitrascu, Alexandra Mihailescu, Roxana Popescu, Mihaela Vlad, Cristian Sebastian Vlad, Camelia Oana Mureşan · 2022 · Pathogens
21. Potent neutralization by monoclonal human IgM against SARS‐CoV‐2 is impaired by class switch
    Ilaria Callegari, Mika Schneider, Giuliano Berloffa, Tobias Mühlethaler, Sebastian Holdermann, Edoardo Galli, Tim C. Roloff, Renate Boss, Laura Infanti, Nina Khanna et al. · 2022 · EMBO Reports
22. Longitudinal study of a SARS-CoV-2 infection in an immunocompromised patient with X-linked agammaglobulinemia
    Laura Ciuffreda, Jose Miguel Lorenzo-Salazar, Julia Alcoba-Flórez, Hector Rodríguez‐Pérez, Helena Gil-Campesino, Antonio Íñigo-Campos, Diego García-Martínez de Artola, Agustı́n Valenzuela-Fernández, Marcelino Hayek Peraza, Susana Rojo‐Alba et al. · 2021 · Journal of Infection
23. N‐terminal domain of SARS CoV‐2 spike protein mutation associated reduction in effectivity of neutralizing antibody with vaccinated individuals
    Yogendra Singh, Neeraj Kumar Fuloria, Shivkanya Fuloria, Vetriselvan Subramaniyan, Dhanalekshmi Unnikrishnan Meenakshi, Srikumar Chakravarthi, Usha Kumari, Navneet Joshi, Gaurav Gupta · 2021 · Journal of Medical Virology
24. Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect In Vivo in a Mouse Model in a Neutralization-Dependent Manner
    Fatima Amanat, Shirin Strohmeier, Wen-Hsin Lee, Sandhya Bangaru, Andrew B. Ward, Lynda Coughlan, Florian Krammer · 2021 · mBio
25. SARS-CoV-2 Variants Associated with Vaccine Breakthrough in the Delaware Valley through Summer 2021
    Andrew D. Marques, Scott A. Sherrill-Mix, J.K. Everett, Shantan G. Reddy, Pascha Hokama, Aoife M. Roche, Young Hwang, Abigail Leigh Glascock, Samantha A. Whiteside, Jevon Graham-Wooten et al. · 2022 · mBio
26. Dynamics of Viral Infection and Evolution of SARS-CoV-2 Variants in the Calabria Area of Southern Italy
    C. de Marco, C. Veneziano, Alice Massacci, Matteo Pallocca, N. Marascio, A. Quirino, G. Barreca, A. Giancotti, L. Gallo, A. Lamberti et al. · 2022 · Frontiers in Microbiology
27. Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development
    Xiao-Huan Liu, Ting Cheng, Baoyu Liu, Jia Chi, Ting Shu, Tao Wang · 2022 · Frontiers in Pharmacology
28. SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19
    Hong-Yu Liang, Yu-Yan Wu, V. Yau, Huan-Xin Yin, S. Lowe, Rachel E. T. Bentley, M. Ahmed, Wenjing Zhao, Chen-Yu Sun · 2022 · Vaccines
29. Comparative susceptibility of SARS-CoV-2, SARS-CoV, and MERS-CoV across mammals
    Meng Li, Juan Du, Weiqiang Liu, Zihao Li, Fei Lv, Chunyan Hu, Yichen Dai, Xiaoxiao Zhang, Zhan Zhang, Gaoming Liu et al. · 2023 · The ISME Journal
30. Interspecies transmission of SARS CoV-2 with special emphasis on viral mutations and ACE-2 receptor homology roles
    Mervat E. Hamdy, Ayman H. El‐Deeb, Naglaa Mohammed Hagag, Momtaz Abdelhady Shahein, Osama Alaidi, Hussein A. Hussein · 2023 · International Journal of Veterinary Science and Medicine
31. Deep mutagenesis scanning using whole trimeric SARS-CoV-2 spike highlights the importance of NTD-RBD interactions in determining spike phenotype
    Ruthiran Kugathasan, Ksenia Sukhova, Maya Moshe, Paul Kellam, William Barclay · 2023 · PLoS Pathogens
32. Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1
    Sijie Yang, Yuanling Yu, Fanchong Jian, Ayijiang Yisimayi, Weiliang Song, Jingyi Liu, Peng Wang, Yanli Xu, Jing Wang, Xiao Niu et al. · 2024 · Emerging Microbes & Infections
33. Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern
    Adonis A. Rubio, Viren A. Baharani, Bernadeta Dadonaite, Megan Parada, Morgan E. Abernathy, Zijun Wang, Yu Erica Lee, Michael R. Eso, Jennie L. Phung, Israel Ramos et al. · 2025 · Science Translational Medicine
34. High Rate of Mutational Events in SARS-CoV-2 Genomes across Brazilian Geographical Regions, February 2020 to June 2021
    Ueric José Borges de Souza, Raíssa Nunes dos Santos, Fabrício Souza Campos, Karine Lima Lourenço, Flávio Guimarães da Fonseca, Fernando Rosado Spilki, Corona-ômica.BR/MCTI Network · 2021 · Viruses
35. Mutational Hotspot in the SARS-CoV-2 Spike Protein N-Terminal Domain Conferring Immune Escape Potential
    Slawomir Kubik, Nils Arrigo, Jaume Bonet, Zhenyu Xu · 2021 · Viruses
36. Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations
    Mohamed A Hendy, Samuel Kaufman, Mauricio Rene Ponga · 2021 · Scientific Reports
37. Mutation-Induced Long-Range Allosteric Interactions in the Spike Protein Determine the Infectivity of SARS-CoV-2 Emerging Variants
    Jayanta Kumar Das, Bikash Thakuri, Krishnan MohanKumar, Swarup Roy, Adnan Sljoka, Gui‐Quan Sun, Amit Chakraborty · 2021 · ACS Omega
38. De novo emergence of SARS‐CoV‐2 spike mutations in immunosuppressed patients
    Lacy M. Simons, Egon Anderson Ozer, Stéphanie Gambut, Taylor J. Dean, Li Zhang, Pavan P. Bhimalli, Jeffrey R. Schneider, João I. Mamede, Michael G. Ison, Reem Karmali et al. · 2022 · Transplant Infectious Disease
39. Real-life data on monoclonal antibodies and antiviral drugs in Italian inborn errors of immunity patients during COVID-19 pandemic
    Giulia Garzi, Francesco Cinetto, Davide Firinu, Giulia Di Napoli, Gianluca Lagnese, Alessandra Punziano, Patrick Bez, Bianca Laura Cinicola, Giulia Anna Maria Luigia Costanzo, Riccardo Scarpa et al. · 2022 · Frontiers in Immunology
40. Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type
    Jozef Dingemans, Brian M. J. W. van der Veer, Koen M. F. Gorgels, Volker Hackert, Audrey Y. J. Hensels, Casper D. J. den Heijer, Christian J. P. A. Hoebe, Paul H. M. Savelkoul, Lieke B. van Alphen · 2022 · Frontiers in Microbiology
41. Omicron-specific ultra-potent SARS-CoV-2 neutralizing antibodies targeting the N1/N2 loop of Spike N-terminal domain
    Xiao Niu, Zhiqiang Li, Jing Wang, Fanchong Jian, Yuanling Yu, Weiliang Song, Ayijiang Yisimayi, Shuo Du, Zhiying Zhang, Qianran Wang et al. · 2024 · Emerging Microbes & Infections
42. SARS-CoV-2 spike mutations alter structure and energetics to modulate ACE2 binding immune evasion and viral adaptation
    Farid Shokry Ataya, Abir Abdullah Alamro, Amani Ahmed Alghamdi, Dalia Fouad · 2025 · Scientific Reports
43. The atomic portrait of SARS‐CoV‐2 as captured by cryo‐electron microscopy
    Tudor Emanuel Fertig, Leona Chiţoiu, George Terinte‐Balcan, Victor Eduard Peteu, Daciana Silvia Marta, Mihaela Gherghiceanu · 2021 · Journal of Cellular and Molecular Medicine
44. Druggable targets and therapeutic development for COVID-19
    Xiaohua Duan, Lauretta A. Lacko, Shuibing Chen · 2022 · Frontiers in Chemistry
45. Comparative analysis of within-host diversity among vaccinated COVID-19 patients infected with different SARS-CoV-2 variants
    Hebah A. Al-Khatib, Maria K. Smatti, Fatma H. Ali, Hadeel T. Zedan, Swapna Thomas, Muna Nizar Ahmed, Reham Awni El Kahlout, Mashael A. Al Bader, Dina Elgakhlab, Peter Valentine Coyle et al. · 2022 · iScience
46. Rapid SARS-CoV-2 Variants Enzymatic Detection (SAVED) by CRISPR-Cas12a
    Jun Yang, Nilakshi Barua, Md. Nannur Rahman, Carmen Li, Norman Wai Sing Lo, Kai-Yan Yeong, Tsz Fung Tsang, Xiao Yang, Yuk‐Yam Cheung, Alan K. L. Tsang et al. · 2022 · Microbiology Spectrum
47. State of the Art in Epitope Mapping and Opportunities in COVID-19
    Samira M. Hamed, Masarra M. Sakr, Ghadir S. El-Housseiny, Reham Wasfi, Khaled M. Aboshanab · 2023 · Future Science OA
48. Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization
    Edwards Pradenas, Sílvia Marfil, Víctor Urrea, Macedonia Trigueros, Tetyana Pidkova, Anna Pons-Grífols, Raquel Ortiz, Carla Rovirosa, Ferran Tarrés-Freixas, Carmen Aguilar‐Gurrieri et al. · 2023 · iScience
49. Convergence of immune escape strategies highlights plasticity of SARS-CoV-2 spike
    Xiaodi Yu, Jarek Juraszek, Lucy Rutten, Mark J. G. Bakkers, Sven Blokland, Jelle M. Melchers, Niels J. F. van den Broek, Annemiek Verwilligen, Pravien D. Abeywickrema, Johan Vingerhoets et al. · 2023 · PLoS Pathogens
50. Challenges in Emerging Vaccines and Future Promising Candidates against SARS‐CoV‐2 Variants
    Tanmay Ghildiyal, Nishant Rai, Janhvi Mishra Rawat, Maargavi Singh, Jigisha Anand, Gaurav Pant, Gaurav Kumar, Amrullah Shidiki · 2024 · Journal of Immunology Research
51. Therapeutic antibodies and alternative formats against SARS-CoV-2
    Rahel R. Winiger, Laurent H. Perez · 2024 · Antiviral Research
52. Deciphering Fc-effector functions against SARS-CoV-2
    Guillaume Beaudoin-Bussières, Andrés Finzi · 2024 · Trends in Microbiology
53. Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens
    Marcos C. Miranda, Elizabeth Kepl, Mary Jane Navarro, Chengbo Chen, Max R. Johnson, Kaitlin R. Sprouse, Cameron Stewart, Anne L. Palser, Adian S. Valdez, Deleah Pettie et al. · 2024 · npj Vaccines
54. Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine
    Spyros Chalkias, Antionette Pragalos, Adebayo Akinsola, Gary Berman, Madhavi Ampajwala, Jay W. Meyer, Lorraine Schoch, Wen Zhou, Yamuna Devi Paila, Weiping Deng et al. · 2025 · The Journal of Infectious Diseases
55. Reverse mutational scanning of SARS-CoV-2 spike BA.2.86 identifies epitopes contributing to immune escape from polyclonal sera
    Najat Bdeir, Tatjana Lüddecke, Henrike Maaß, Stefan Schmelz, Ulfert Rand, Henning Jacobsen, Kristin Metzdorf, Upasana Kulkarni, Anne Cossmann, Metodi V. Stankov et al. · 2025 · Nature Communications
56. Immunology of SARS-CoV-2 infections and vaccines
    Dominik Schenten, Deepta Bhattacharya · 2021 · Advances in immunology
57. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination
    Pinja Jalkanen, Pekka Kolehmainen, Anu Haveri, Moona Huttunen, Larissa Laine, Pamela Österlund, Paula A. Tähtinen, Lauri Ivaska, Sari Maljanen, Arttu Reinholm et al. · 2022 · Microbiology Spectrum
58. Antibody response and intra‐host viral evolution after plasma therapy in COVID ‐19 patients pre‐exposed or not to B‐cell‐depleting agents
    David Gachoud, Trestan Pillonel, Γεράσιμος Τσιλιμιδός, Dunia Battolla, Dominique Dumas, Onya Opota, Stefano Fontana, Péter Vollenweider, Oriol Manuel, Gilbert Greub et al. · 2022 · British Journal of Haematology
59. Humoral immunity for durable control of SARS-CoV-2 and its variants
    Ryutaro Kotaki, Saya Moriyama, Yoshimasa Takahashi · 2023 · Inflammation and Regeneration
60. SARS‐CoV‐2 variants and spike mutations involved in second wave of COVID‐19 pandemic in India
    R. Muttineni, Binitha R. N., Kalyani Putty, K. Marapakala, Sandra K. P., Jaslin Panyam, Aravind Vemula, Shashikant Singh, S. Balachandran, Viroji Rao St et al. · 2022 · Transboundary and Emerging Diseases
61. Genomic epidemiology of SARS-CoV-2 in Mauritius reveals a new wave of infections dominated by the B.1.1.318, a variant under investigation
    Houriiyah Tegally, Magalutcheemee Ramuth, Daniel Amoaka, Cathrine Scheepers, Eduan Wilkinson, Marta Giovanetti, Richard J. Lessells, Jennifer Giandhari, Arshad Ismail, Darren Patrick Martin et al. · 2021 · medRxiv
62. Binding of Glycans to the SARS CoV‐2 Spike Protein, an Open Question: NMR Data on Binding Site Localization, Affinity, and Selectivity
    Thorben Maaß, George Liam Ssebyatika, Marlene Brückner, Lea Breckwoldt, Thomas Krey, Álvaro Mallagaray, Thomas Peters, Martin Frank, Robert Creutznacher · 2022 · Chemistry - A European Journal
63. Neutralizing and enhancing antibodies against SARS-CoV-2
    Yafei Liu, Hisashi Arase · 2022 · Inflammation and Regeneration
64. Evolution of Sequence and Structure of SARS-CoV-2 Spike Protein: A Dynamic Perspective
    Anushree Sinha, Satyam Sangeet, Susmita Roy · 2023 · ACS Omega
65. Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation
    Hung Van Nguyen, Hoang Linh Nguyen, Pham Dang Lan, Nguyen Quoc Thai, Mateusz Sikora, Mai Suan Li · 2023 · Chemical Society Reviews
66. Multi-structural molecular docking (MOD) combined with molecular dynamics reveal the structural requirements of designing broad-spectrum inhibitors of SARS-CoV-2 entry to host cells
    Anqi Da, Meritxell Wu‐Lu, Jovan Lj. Dragelj, María Andrea Mroginski, Kourosh Honarmand Ebrahimi · 2023 · Scientific Reports
67. Single-Molecule Investigation of the Binding Interface Stability of SARS-CoV-2 Variants with ACE2
    A. Ray, Thu Thi Minh Tran, Rita Dos Santos Natividade, Rodrigo A. Moreira, J. D. Simpson, Danahe Mohammed, Melanie Koehler, S. Petitjean, Qingrong Zhang, F. Bureau et al. · 2024 · ACS Nanoscience Au
68. Viral Population Heterogeneity and Fluctuating Mutational Pattern during a Persistent SARS-CoV-2 Infection in an Immunocompromised Patient
    Martina Brandolini, Silvia Zannoli, Giulia Gatti, Valentina Arfilli, Monica Cricca, Giorgio Dirani, Agnese Denicolò, Simona Semprini, Laura Grumiro, Manuela Imola et al. · 2023 · Viruses
69. The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice
    Dimitrina Miteva, Meglena Kitanova, Hristiana Batselova, Snezhina Lazova, Lyubomir Chervenkov, Monika Peshevska-Sekulovska, Metodija Sekulovski, Milena Gulinac, Georgi Vasilev, L Tomov et al. · 2023 · Vaccines
70. How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika
    M. Abernathy, K. A. Dam, S. Esswein, C. A. Jette, P. Bjorkman · 2021 · Viruses
71. ViruClust: direct comparison of SARS-CoV-2 genomes and genetic variants in space and time
    Luca Cilibrasi, Pietro Pinoli, Anna Bernasconi, Arif Canakoglu, Matteo Chiara, Stefano Ceri · 2022 · Bioinformatics
72. A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery
    Dora Pinto, Maximilian M. Sauer, Nadine Czudnochowski, Jun Siong Low, M. Alejandra Tortorici, Michael Patrick Housley, Julia Noack, Alexandra C. Walls, John E. Bowen, Barbara Guarino et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
73. SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usage
    Ruoke Wang, Qi Zhang, Jiwan Ge, Wenlin Ren, Rui Zhang, Jun Lan, Bin Ju, Bin Su, Fengting Yu, Peng Chen et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
74. SARS-CoV-2 cell-to-cell spread occurs rapidly and is insensitive to antibody neutralization
    Laurelle Jackson, Hylton E. Rodel, Shi-Hsia Hwa, Sandile Cele, Yashica Ganga, Houriiyah Tegally, Mallory P. Bernstein, Jennifer Giandhari, COMMIT-KZN Team, Bernadett Isabel Gosnell et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
75. Structural and functional characterizations of altered infectivity and immune evasion of SARS-CoV-2 Omicron variant
    Zhen Cui, Pan Liu, Nan Wang, Lei Wang, Kaiyue Fan, Qianhui Zhu, Kang Wang, Ruihong Chen, Rui Feng, Zijing Jia et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
76. Optimizing a human monoclonal antibody for better neutralization of SARS-CoV-2
    Wang, Qian, Guo, Yicheng, Casner, Ryan G., Yu, Jian, Nair, Manoj S., Ho, Jerren, Reddem, Eswar R., Mellis, Ian A., Wu, Madeline, Tzang, Chih-Chen et al. · 2025 · Nature Communications
77. Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines
    Mohammad Reza Sepand, Banafsheh Bigdelou, Jim Q. Ho, Mohammad Sharaf, Alexis J. Lannigan, Ian M. Sullivan, Alecsander P. da Silva, Leland O. Barrett, Scott McGoldrick, Yuvraj Lnu et al. · 2022 · Antibodies
78. SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments
    Xinyi Wang, Jing-Wen Li, Hanshu Liu, Xin-Yu Hu, Zhi-Cheng Lin, N. Xiong · 2023 · Microorganisms
79. Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
    J. Seow, Z. A. Shalim, C. Graham, Simon Kimuda, Aswin Pillai, T. Lechmere, Ashwini Kurshan, Atika M. Khimji, L. Snell, G. Nebbia et al. · 2023 · mBio
80. Evolutionary deletions within the SARS-CoV-2 genome as signature trends for virus fitness and adaptation
    Pedro Miguel Carneiro Jerônimo, Cleber Furtado Aksenen, Igor Oliveira Duarte, Roberto Dias Lins, Fábio Miyajima · 2023 · Journal of Virology
81. Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features
    Craig A. Magaret, Li Li, Allan C. deCamp, Morgane Rolland, Michal Juraska, Brian D. Williamson, James Ludwig, Cindy Molitor, David C. Benkeser, Alex R. Luedtke et al. · 2024 · Nature Communications
82. Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection
    Michael Schöfbänker, Theresa Günther, Eva Ulla Lorentzen, Marie-Luise Romberg, Marc Tim Hennies, Rieke Neddermeyer, Marlin Maybrit Müller, Alexander Mellmann, Chiara Robin Bojarzyn, Georg Lenz et al. · 2024 · PLoS Pathogens
83. SARS-CoV-2 serotyping based on spike antigenicity and its implications for host immune evasion
    Wenjing Ruan, Pengyue Gao, Xiao Qu, Junlan Jiang, Zhennan Zhao, Shitong Qiao, He Zhang, Ting Yang, Dedong Li, Pei Du et al. · 2025 · EBioMedicine
84. SARS-related coronavirus S-protein structures reveal synergistic RBM interactions underpinning high-affinity human ACE2 binding
    Jingjing Wang, Yong Ma, Zimu Li, Hang Yuan, Banghui Liu, Zexuan Li, Mengzhen Su, Gul Habib, Yutong Liu, Lutang Fu et al. · 2025 · Science Advances
85. Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models
    Young-Il Kim, Mark Anthony B. Casel, Young-Ki Choi · 2022 · Journal of Microbiology
86. Progressive membrane-binding mechanism of SARS-CoV-2 variant spike proteins
    Michael Overduin, Troy A. Kervin, Anh Tran · 2022 · iScience
87. Conformational stability of SARS-CoV-2 glycoprotein spike variants
    Hiam R. S. Arruda, Túlio M. Lima, Renata G. F. Alvim, Fernanda B. A. Victorio, Daniel Paiva Barros de Abreu, Federico Francisco Marsili, Karen D. Cruz, Mayra A. Marques, Patricia Sosa‐Acosta, Mauricio Quiñones‐Vega et al. · 2022 · iScience
88. Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape
    Roberta Marzi, Jessica Bassi, Chiara Silacci-Fregni, István Bartha, Francesco Muoio, Katja Culap, Nicole Sprugasci, Gloria Lombardo, Christian Saliba, Elisabetta Cameroni et al. · 2022 · iScience
89. Network analysis uncovers the communication structure of SARS-CoV-2 spike protein identifying sites for immunogen design
    Pedro D. Manrique, Srirupa Chakraborty, Rory C. Henderson, Robert J. Edwards, Rachael A. Mansbach, Kien Nguyen, Victoria Stalls, Carrie Saunders, Katayoun Mansouri, Priyamvada Acharya et al. · 2022 · iScience
90. Scope of repurposed drugs against the potential targets of the latest variants of SARS-CoV-2
    Vidya Niranjan, Anagha Shamsundar Setlur, K. S. Chandrashekar, Akshay Uttarkar, Kalavathi Murugan Kumar, Sinosh Skariyachan · 2022 · Structural Chemistry
91. Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
    Simone Pecetta, Sven Kratochvil, Yu Kato, Kumaran Vadivelu, Rino Rappuoli · 2022 · Pharmacological Reviews
92. COVID‐19: An Overview of SARS‐CoV‐2 Variants—The Current Vaccines and Drug Development
    Narjess Bostanghadiri, Pardis Ziaeefar, Morvarid Golrokh Mofrad, Parsa Yousefzadeh, Ali Hashemi, Davood Darban‐Sarokhalil · 2023 · BioMed Research International
93. The Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution
    Ying Liu, Qing Ye · 2023 · Vaccines
94. Unraveling the Dynamics of Omicron (BA.1, BA.2, and BA.5) Waves and Emergence of the Deltacron Variant: Genomic Epidemiology of the SARS-CoV-2 Epidemic in Cyprus (Oct 2021–Oct 2022)
    Andreas C. Chrysostomou, Bram Vrancken, Christos Haralambous, Maria Alexandrou, Ioanna Gregoriou, Marios Ioannides, Costakis Iοannou, Olga Kalakouta, Christos Karagiannis, Markella Marcou et al. · 2023 · Viruses
95. Antibodies to S2 domain of SARS-CoV-2 spike protein in Moderna mRNA vaccinated subjects sustain antibody-dependent NK cell-mediated cell cytotoxicity against Omicron BA.1
    Corey A. Balinsky, Le Jiang, Vihasi Jani, Ying Cheng, Zhiwen Zhang, Tatyana Belinskaya, Qi Qiu, Tran Khanh Long, Megan A. Schilling, Sarah A. Jenkins et al. · 2023 · Frontiers in Immunology
96. Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies
    Tetsuya Inoue, Yuichiro Yamamoto, Kaoru Sato, Yuko Okemoto‐Nakamura, Yoshimi Shimizu, Motohiko Ogawa, Taishi Onodera, Yoshimasa Takahashi, Takaji Wakita, Mika Kato Kaneko et al. · 2024 · iScience
97. An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants
    Nathaniel L. Miller, Thomas Clark, Rahul Raman, Ram Sasisekharan · 2021 · Viruses
98. Contributions of single-particle cryoelectron microscopy toward fighting COVID-19
    Micah Rapp, Lawrence S. Shapiro, Joachim Frank · 2021 · Trends in Biochemical Sciences
99. A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant
    Nitin K Hingankar, Suprit Deshpande, Payel Das, Zaigham Abbas Rizvi, C. K. Wibmer, Poppy Mashilo, M. Y. Ansari, Alison Burns, Shawn Barman, Fang-Zhu Zhao et al. · 2021 · bioRxiv
100. Infection pre-Ad26.COV2.S-vaccination primes greater class switching and reduced CXCR5 expression by SARS-CoV-2-specific memory B cells
     Robert G. E. Krause, Thandeka Moyo-Gwete, Simone I. Richardson, Zanele Makhado, Nelia P. Manamela, Tandile Hermanus, Nonhlanhla N. Mkhize, Roanne S. Keeton, Ntombi Benede, Mathilda Mennen et al. · 2023 · npj Vaccines